lymphatic filariasis / dengue

lymphatic filariasis

Provision of medicine to treat lymphatic filariasis free of charge

In November 2010, Eisai agreed to provide 2.2 billion tablets of diethylcarbamazine (DEC), a medicine for treating lymphatic filariasis, to the World Health Organization (WHO) for free. Based on that agreement, Eisai used its factory in India to manufacture DEC tablets, and began providing them to countries where lymphatic filariasis is endemic in October 2013. In February 2016, a new public-private partnership has been initiated to provide diagnostic kits free of charge, for use in evaluating the success of mass drug administration (MDA) in LF elimination and helping to determine when MDA can stop. Eisai is also taking part in the partnership. Through the supply of DEC tablets and diagnostic kits, Eisai is contributing to the global program to eliminate lymphatic filariasis. More information is avalilable at

Development of medicine for treating Filariasis Eisai commenced research in collaboration with the Liverpool School of Tropical Medicine and the University of Liverpool to jointly identify new drugs effective against lymphatic filariasis and onchocerciasis (river blindness), both major types of filariasis. The goal is to develop a treatment that can effectively eradicate the worms that cause filariasis by first eliminating theWolbachia bacteria inside them which the worms (filariae) depend upon for growth, development and survival.


Development of vaccine for treating dengue fever Takeda is conducting a pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial to evaluate the safety and efficacy of two doses of Takeda's dengue vaccine candidate (TAK-003) in the prevention of laboratory-confirmed symptomatic dengue fever due to any of the four dengue virus serotypes in children and adolescents.

The 18-month data analysis from the pivotal Phase 3 TIDES trial includes an update on overall vaccine efficacy (VE) and a formal assessment of secondary efficacy endpoints by serotype, baseline serostatus and disease severity (18 months after the second dose, which was administered three months after the first dose), demonstrating protection against virologically confirmed dengue (VCD) in children ages four to 16 years. Takeda plans to share results from the 24-month analysis of TIDES in later 2020. Takeda’s dengue vaccine candidate is not currently licensed anywhere in the world (as of July 2020).